Exact Sciences’ experience with the FDA and CMS parallel review program

References

• Cancer facts & figures 2015. American Cancer Society, Atlanta, GA; 2015. Available from: www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf [Last accessed 12 May 2015]
   Google Scholar
• Mariotto AB, Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States 2010–2020. J Natl Cancer Inst 2011;103:117-28
   PubMed Web of Science ®Google Scholar
• U.S. Preventative Services Task Force. Screening for colorectal cancer: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance. The state of health care quality 2014, Washington, DC; 2014. Available from: www.ncqa.org/Portals/0/Newsroom/2014/SOHC-web.pdf [Last accessed 11 May 2015]
   Google Scholar
• Centers for Disease Control and Prevention. Vital signs: colorectal cancer screening test use – United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:881-8
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Vigan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med 2012;172:575-82
   PubMed Web of Science ®Google Scholar
• Cologuard [package insert]. Exact Sciences Corporation, Madison, WI; 2013. Available from: www.accessdata.fda.gov/cdrh_docs/pdf13/P130017c.pdf [Last accessed 5 May 2015]
   Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Melotte V, Lentjes MH, van den Bosch SM, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 2009;101:916-27
   PubMed Web of Science ®Google Scholar
• miRBase Sequence database, release 21.0. Available from: ftp://mirbase.org/pub/mirbase/CURRENT/ [Last accessed 12 May 2015]
   Google Scholar
• Ahlquist D, Zou H, Domanico M, et al. Next generation stool DNA testing for detection of colorectal neoplasia: early marker evaluation. Presented at: American Association of Cancer Research; 29 October 2010; Philadelphia, PA
   Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-97
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. for the Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Guidance for industry and FDA staff: commercially distributed analyte specific reagents (ASRs): frequently asked questions. U.S. Food and Drug Administration, Rockville, MD; 2007. Available from: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm078423.htm [Last accessed 15 April 2015]
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Draft guidance for industry, U.S. Food and Drug Administration staff, and clinical laboratories: framework for regulatory oversight of laboratory developed tests (LDTs). U.S. Food and Drug Administration, Silver Spring, MD; 2014. Available from: www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm416685.pdf [Last accessed 15 April 2015]
   Google Scholar
• Overview of IVD regulation. U.S. Food and Drug Administration, Silver Spring, MD; 2015. Available from: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm123682.htm#9 [Last accessed 4 April 2015]
   Google Scholar
• Pathway to commercialization for an in vitro diagnostic (IVD) in the US. MaRS Discovery District, Toronto, ON; 2010. Available from: www.marsdd.com/wp-content/uploads/2012/09/Pathway-to-Commercialization-for-an-In-Vitro-Diagnostic-in-the-US.pdf [Last accessed 2 April 2015]
   Google Scholar
• Premarket approval (PMA). U.S. Food and Drug Administration, Silver Spring, MD; 2014. Available from: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/default.htm [Last accessed 4 April 2015]
   Google Scholar
• Agenda for quarterly meeting on MDUFA III (FY 2013-2017) performance. U.S. Food and Drug Administration, Silver Spring, MD; 2015. Available from: www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Overview/MedicalDeviceUserFeeandModernizationActMDUFMA/UCM432970.pdf [Last accessed 27 April 2015]
   Google Scholar
• Technology Evaluation Center (TEC). Blue Cross Blue Shield, Chicago, IL; 2015. Available from: www.bcbs.com/blueresources/tec/ [Last accessed 15 April 2015]
   Google Scholar
• Lindor RA, Allocco SJ, Cheatham L, et al. Regulatory and reimbursement innovation. Sci Transl Med 2013;5:176cm3
   PubMed Web of Science ®Google Scholar
• Bassu S, Hassenplug J. Patient access to medical devices — a comparison of U.S. and European review processes. N Engl J Med 2012;367:485-8
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. National Coverage Annual Report. 2015. Available from: www.cms.gov/medicare-coverage-database/reports/national-coverage-annual-report.aspx?bc=AQAAAAAAAAAAAA%3d%3d& [Last accessed 21 May 2015]
   Google Scholar
• Sebelius K. Report to Congress on Medicare national coverage determinations for fiscal year 2013. 2014. Available from: www.cms.gov/Medicare/Coverage/InfoExchange/Downloads/2013-Report-To-Congress.pdf [Last accessed 1 April 2015]
   Google Scholar
• Pilot program for parallel review of medical products [Docket No. FDA-2010-N-0308]. Federal Register 2011;76:62808-10
   Google Scholar
• Messner DA, Tunis SR. Current and future state of FDA-CMS parallel reviews. Clin Pharmacol Ther 2012;91:383-5
   PubMed Web of Science ®Google Scholar
• Hochberg D, Kolman O. Cologuard reimbursement analogs. Health Advances LLC, Weston, MA; 2015
   Google Scholar
• U.S. Department of Health & Human Services, Centers for Medicare & Medicaid Services. 2014. CMS statistics [CMS Pub No. 03510] Available from: www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Statistics-Reference-Booklet/Downloads/CMS_Stats_2014_final.pdf#tablei2 [Last accessed 16 April 2015]
   Google Scholar
• Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) level II coding procedures. 2012. Available from: www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/downloads/HCPCSLevelIICodingProcedures7-2011.pdf [Last accessed 4 May 2015]
   Google Scholar
• Exact Sciences: additional update on CMS reimbursement for Cologuard^® [press release]. Exact Sciences Corporation, Madison, WI; 2015. Available from: http://investor.exactsciences.com/releasedetail.cfm?releaseid=889245 [Last accessed 14 April 2015]
   Google Scholar
• Applying for CPT^® Codes. American Medical Association, Chicago, IL. Available from: www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-insurance/cpt/applying-cpt-codes.page [Last accessed 14 April 2015]
   Google Scholar
• Dhruva SS, Phurrough SE, Salive ME, Redberg RF. CMS’s landmark decision on CT colonography — examining the relevant data. N Eng J Med 2009;360:2699-701
   PubMed Web of Science ®Google Scholar
• Chambers JD, Chenoweth M, Cangelosi MJ, et al. Medicare is scrutinizing evidence more tightly for national coverage determinations. Health Aff 2015;34:253-60
   Web of Science ®Google Scholar